Renal Angiomyolipoma
📧 Sign up to get email alerts when something new happens for Renal Angiomyolipoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Superselective Renal Artery Embolization for Renal Angiomyolipoma
A clinical trial update for a study evaluating selective endovascular embolization of the kidney artery to treat renal angiomyolipoma; the t…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) [Phase 4]
Phase IV study assessing the safety and efficacy of Everolimus in Taiwanese patients with tuberous sclerosis complex-associated renal angiom…
-
CLINICAL_TRIALS other · 2026-03-30Clinical Trial Update: Evaluation of a Simple-Prep Controlled Embolic [NA]
This clinical trial update indicates ongoing evaluation of a simple-prep controlled embolic device; the study is currently active but not re…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. [Phase 4]
Phase 4 trial assessing safety and efficacy of Everolimus (Afinitor) in Chinese adults with angiomyolipoma associated with tuberous sclerosi…
-
CLINICAL_TRIALS trial_result · 2018-01-23Clinical Trial Update: Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers [Phase 2]
Phase 2 trial evaluating beta-blockers for treatment of renal angiomyolipomas in tuberous sclerosis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-07-01FDA Approved: AFINITOR DISPERZ — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application to add Afinitor Disperz, the dispersible tablet form of everolimus, expanding formulation options fo…